Press release
Small Interfering RNA (siRNA) Therapeutics Market to Reach US$ 12.38 Billion by 2033, Growing at 17.4% CAGR
Small Interfering RNA (siRNA) Therapeutics Market
siRNA drugs operate by silencing disease-causing genes at the post-transcriptional level, preventing harmful protein production. Since the FDA's 2018 approval of patisiran (Onpattro), the market has seen a steady stream of breakthroughs. The most recent milestone occurred in March 2025, with the U.S. FDA approving fitusiran (Qfitlia) for hemophilia A and B, marking the first siRNA therapy in the hemophilia treatment landscape.
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/small-interfering-rna-therapeutics-market?utm_source=OpenPR&utm_campaign=Onkar
Key Highlights from the Report
➤ Global siRNA market expected to grow at 17.4% CAGR, reaching US$ 12.38 billion by 2033
➤ Vutrisiran (Amvuttra) leads with 38.05% market share and US$ 970.45 million sales in 2024
➤ North America holds 52.2% market share, driven by U.S. dominance in approvals and sales
➤ Seven siRNA therapies approved globally; more expected during forecast period
➤ Emerging pipeline therapies target wider range of genetic and rare diseases
➤ March 2025 FDA approval of Fitusiran marks breakthrough for hemophilia treatment
Market Segmentation
The siRNA therapeutics market is segmented by drug, indication, route of administration, and region.
By drug, Vutrisiran (Amvuttra) dominates, approved for hereditary transthyretin-mediated amyloidosis (hATTR) and cardiomyopathy. Developed by Alnylam Pharmaceuticals, it has shown transformative impact in reducing cardiovascular mortality and hospitalizations. In 2024, it achieved US$ 970.45 million in total sales, with nearly 65% revenue from the U.S. market.
By indication, siRNA treatments address conditions with high unmet needs, including amyloidosis, hemophilia, and hypercholesterolemia. New therapy development focuses on expanding into broader chronic illnesses with genetic roots, offering potential to scale commercial adoption.
Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/small-interfering-rna-therapeutics-market?utm_source=OpenPR&utm_campaign=Onkar
Regional Insights
North America leads the global market, accounting for 52.2% share in 2024, reflecting both high disease prevalence and strong regulatory and commercial activity. All approved siRNA drugs are available in the U.S., and revenues from the region are substantial:
Europe is also expanding rapidly, driven by EMA approvals and health system uptake. In April 2025, the European Medicines Agency (CHMP) granted a positive opinion recommending Vutrisiran for ATTR-CM cardiomyopathy treatment.
Asia-Pacific shows significant potential, with improving regulatory frameworks and biopharma collaboration driving faster introduction of advanced RNA therapies into regional markets.
Market Dynamics
Market Drivers
Rising global incidence of rare genetic diseases and demand for precision therapies underpin growth. Increasing funding for biopharma R&D and expansion of approved siRNA indications amplify opportunities.
Market Restraints
High treatment costs remain a barrier, as drugs like Onpattro cost over US$ 10,000 per infusion, posing affordability challenges in low- and middle-income countries.
Market Opportunities
Next-generation delivery systems, subcutaneous formulations, and expanding therapeutic applications into chronic lifestyle diseases present lucrative growth avenues for industry players.
Purchase This Exclusive Report at Just USD 4391 Only: https://www.datamintelligence.com/buy-now-page?report=small-interfering-rna-therapeutics-market?utm_source=OpenPR&utm_campaign=Onkar
Reasons to Buy the Report
✔ Detailed insight into current approved siRNA therapies and clinical pipeline developments
✔ Analysis of pricing models, reimbursement trends, and market access challenges
✔ Breakdown of market share by drug, region, and indication for strategic planning
✔ Competitive benchmarking of leading and emerging siRNA developers
✔ Identification of innovation opportunities in delivery platforms and patient outreach
Frequently Asked Questions (FAQs)
◆ How big is the global siRNA therapeutics market in 2024?
◆ Who are the leading companies in the RNA-based drug development sector?
◆ What CAGR is projected for the siRNA market from 2025-2033?
◆ Which siRNA therapy currently holds the largest market share?
◆ Which region will dominate the global siRNA therapeutics market by 2033?
Company Insights
Alnylam Pharmaceuticals, Inc.
Novartis AG
Novo Nordisk A/S
Emerging Players:
Arbutus Biopharma
ADARx Pharmaceuticals
Arrowhead Pharmaceuticals, Inc.
Amgen Inc.
Recent Developments:
April 2025 - CHMP (EMA) adopts positive opinion recommending Vutrisiran for ATTR-CM cardiomyopathy treatment.
March 2025 - FDA approves Fitusiran (Qfitlia) for hemophilia A and B, marking first siRNA therapy in hemophilia treatment landscape.
Conclusion
The global siRNA therapeutics market is entering an era of accelerated growth as breakthrough drugs expand beyond rare diseases into broader care segments. North America's leadership combined with Europe's regulatory momentum and Asia-Pacific's fast-developing biotech ecosystem sets the stage for robust market performance. With rapid innovation in delivery technologies and new approvals anticipated, siRNA drugs are poised to redefine the landscape of genetic and chronic disease management through 2033.
Contact Us
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com
About Us
DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Small Interfering RNA (siRNA) Therapeutics Market to Reach US$ 12.38 Billion by 2033, Growing at 17.4% CAGR here
News-ID: 4211938 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
United States Intravenous Anticoagulants Market to Reach USD 20.1 Billion by 203 …
The Intravenous Anticoagulants Market is anticipated to reach at a high CAGR during the forecast period.
The Intravenous Anticoagulants market focuses on medications administered through IV to prevent or treat blood clots. These anticoagulants, such as heparin and direct thrombin inhibitors, are essential in managing conditions like deep vein thrombosis, pulmonary embolism, and during surgeries to reduce clotting risks. The market is driven by the rising prevalence of cardiovascular diseases, advancements…
United States Biorational Pesticides Market to Reach US$ 18.85 Billion by 2031, …
Global Biorational Pesticides Market reached US$ 6.12 billion in 2023 and is expected to reach US$ 18.85 billion by 2031, growing with a CAGR of 15.1% during the forecast period 2024-2031.
Biorational Pesticides Market includes natural or minimally toxic pesticides derived from microbes, plant extracts, or biochemical agents. Growth is driven by sustainable agriculture, regulatory restrictions on chemical pesticides, and organic farming trends. Applications include pest control in fruits, vegetables, and…
United States Orthopedic Software Market to Reach USD 530.31 Million by 2031, Gr …
The Orthopedic Software Market is valued at a significant CAGR during the forecast period (2024-2031).
Orthopedic software is specialized technology used in healthcare to manage, diagnose, and treat musculoskeletal disorders and injuries. This software helps orthopedic surgeons with patient data management, preoperative planning, surgical navigation, and post-operative care. It provides tools for imaging, such as X-rays and MRIs, to assist in diagnosing bone fractures, joint issues, and other orthopedic conditions. The…
United States Hydrotreating Catalysts Market to Reach USD 1.74 Billion by 2031, …
Global Hydrotreating Catalysts Market reached US$ 1,284.2 million in 2023 and is expected to reach US$ 1,735.5 million by 2031, growing with a CAGR of 4.0% during the forecast period 2024-2031.
Hydrotreating Catalysts Market involves catalysts used in refining petroleum to remove sulfur, nitrogen, and impurities. Growth is driven by fuel quality regulations, refinery upgrades, and cleaner fuel demand. Catalysts improve efficiency, yield, and environmental compliance. Refineries and chemical plants are…
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
